This communication describes the anti-platelet effects of a new class of cis-rhenium(II)-dicarbonyl-vitamin B 12 complexes with tuneable CO releasing properties.Carbon-monoxide releasing molecules (CORMs) represent an innovative class of compounds which attract interest due to their potential therapeutic utility. Unlike most common drugs whose pharmacological action is dependent on their interaction with a macromolecular target and whose potency is dictated by the stability of the drug-target complex, CORMs exert their therapeutic action via the liberated CO molecules. [1][2][3][4][5] However, apart from the common scientific consensus that CORM-based therapy should not lead to significant carboxyhemoglobin (COHb) formation and to the inhibition of respiratory enzymes that are sensitive to CO, it is questionable whether CORMs should release CO slowly or rapidly and what kinetics of CO release is most advantageous for therapeutic applications. There are only few reports clearly showing the advantages of CORMs slowly releasing CO over those releasing CO instantly 6,7 and they relate to the anti-platelet effects of CORMs. Furthermore, it has proved chemically challenging to fine-tune the activation and the rate of CO release within a family of structurally similar CORM compounds. For all of these reasons, versatile classes of CORMs with tuneable release properties affording anti-platelet activity are highly desired for tackling these open questions in systematic structure-activity relationship studies. Such studies will facilitate the development of CORMs with optimal antiplatelet activity. -(CO) 2 fragment. This approach seemed to be reasonable because small variations in the coordination sphere of rhenium complexes have profound consequences on the electrochemistry, water stability and CO releasing properties of the dicarbonyl core.17 B 12 appeared to be attractive as ligand for the rhenium-based CORM entity mainly because of two reasons: (a) its cellular uptake properties can be exploited to deliver therapeutic agents specifically at disease sites; 18-20 (b) the electronic properties at the cobalt center can be selectively modified by introducing structural modifications at the corrin-p-system.
21-24Having the general design of the B 12 -ReCORMs derivatives in mind (Scheme 1), we synthesized and studied first a series of Scheme 1 General design concept for the tuneable activation of CORMbiovectors conjugates.